Table 2. Laboratory values (median (IQR)).
| Variable | Baseline (n = 56) | EOT (n = 40) | 12 w (n = 29) | 24 w (n = 20) | 48 w (n = 14) |
| AFP, ng/mL | 7.2 (4.2–13.4) | 4.2 (2.7–6.3) | 4.2 (2.9–6.8) | 5.1 (2.8–7.5) | 3.7 (3.1–4.9) |
| Viral load, IU/mL | 1200000 (362000–4200000) | 0 (0–0) | 0 (0–0) | 0 (0–0) | NA (NA–NA) |
| Platelet count, 103/μL | 95 (60–131.5) | 93 (62–141) | 107 (78–153) | 119 (80–167.5) | 104.5 (71–164) |
| Albumin, g/dL | 3.7 (3.2–4) | 3.7 (3.3–4.2) | 4 (3.5–4.4) | 4 (3.8–4.4) | 4 (3.4–4.5) |
| INR | 1.2 (1.1–1.2) | 1.2 (1.1–1.2) | 1.2 (1.1–1.2) | 1.2 (1.1–1.2) | 1.2 (1.1–1.3) |
| AST, U/L | 60 (39.5–87.5) | 31 (27–41.5) | 28 (21–36) | 26 (23–33) | 30 (25.5–39.2) |
| ALT, U/L | 48 (31.8–75) | 25 (19.5–33) | 21 (16–28) | 22 (20–27) | 24.5 (19.8–30.5) |
| Total bilirubin, mg/dL | 0.9 (0.6–1.7) | 0.9 (0.5–1.6) | 0.7 (0.5–1.3) | 0.7 (0.5–1.3) | 1 (0.4–1.8) |
| Serum creatinine, mg/dL | 0.8 (0.7–1) | 0.9 (0.7–1) | 0.8 (0.7–1) | 0.9 (0.8–1) | 0.9 (0.8–1) |
| Alkaline phosphatase, U/L | 103 (76–142.2) | 103 (72.5–140.5) | 101 (75–114) | 96 (69–134) | 86 (72.2–114.8) |
| Hemoglobin, g/dL | 13.2 (12.1–14) | 12.7 (11.3–14.3) | 13 (11.8–13.5) | 14.1 (12.8–14.8) | 13.8 (12.2–14.4) |
| MELD | 10.1 (7.5–12) | — | — | — | — |
| FIB4 | 6.1 (4.1–10.3) | — | — | — | — |
| APRI | 1.5 (0.8–3.2) | — | — | — | — |
| Sodium, mmol/L | 139 (137–141) | — | — | — |
Abbreviations: SVR12, sustained virological response at 12 weeks; AST, aspartate transaminase; ALT, alanine transaminase; AFP, alpha-fetoprotein; INR, international normalized ratio; MELD, model for end-stage liver disease; Na, sodium; FIB4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.